Page URL: https://www.bionews.org.uk/page_144561

Mitochondria linked to stem cell transplant rejection

27 August 2019
Appeared in BioNews 1012

A new study has shown why stem cell transplants, even derived from the patient's own cells can be rejected. 

Induced pluripotent stem cells (iPSCs) are adult cells treated to regain the properties of stem cells, which have enormous therapeutic potential. However, the process by which cells are converted into iPSCs is known to introduce mutations, and mitochondria are especially susceptible. 

'Under normal physiological conditions, mitochondrial DNA is 10 to 20 times more susceptible to mutation than nuclear DNA. Transforming adult cells into stem cells is a harsh process, so we expected mutation rates to be just as high or higher,' said co-lead author Professor Tobias Deuse at the University of California, San Francisco (UCSF). 

Although mitochondria contain only 17 genes, they are very plentiful in some cells types, meaning that they can be disproportionately represented in the transcriptome. 

'In cells that do a lot of work, like heart muscle cells, up to a third of the cell's protein-producing mRNA molecules are mitochondrial in origin. This means that the burden of a single mitochondrial mutation may be tremendous. You don't end up with just a few proteins that can potentially provoke an immune response – you end up with thousands,' said senior author Professor Sonja Schrepfer also at UCSF.

The researchers conducted experiments in mice, where stem cells were created that perfectly matched the recipient mouse's nuclear DNA but differed by a single base-pair in two mitochondrial genes. Immune cells were retrieved a few days after to cells were introduced to the mice, and tested against various mitochondria protein fragments. Only samples containing the proteins produced from the changed genes triggered a response. 

To test the hypothesis in humans, the researchers looked at kidney and liver transplant recipients, where the mitochondrial genome differed between the donor and the recipient. They were able to isolate immune cells from the transplant recipients and see the same response to the mitochondrial proteins that matched the donor, but not the recipient DNA. Even a change of one base was sufficient. 

'The bottom line is that we want to make people aware of this phenomenon. Just because iPSCs are derived from your own cells doesn't necessarily mean they won't induce an immune response. It's very easy to introduce mutations during iPSC production, so it's critical that iPSC and stem cell products used therapeutically are screened for mitochondrial mutations prior to transplant,' said the authors.

The international team published the study in Nature Biotechnology.

SOURCES & REFERENCES
De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans
Nature Biotechnology |  19 August 2019
New Clues on Stem Cell Transplant Rejection Revealed in Study
University of California, San Francisco |  19 August 2019
New study reveals causes of stem cell transplant rejection
Drug Target Review |  20 August 2019
Stem cells could regenerate organs – but only if the body won't reject them
The Conversation |  19 August 2019
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
12 November 2018 - by Martha Henriques 
A male patient in his fifties has received a stem cell injection into the brain in an early phase trial for Parkinson's disease...
4 June 2018 - by Dr Nicoletta Charolidi 
The first in utero stem cell transplant trial has welcomed its first baby - born after being treated in the womb with her mother's stem cells...
20 November 2017 - by Dr Patrick Foong 
Stem cell research holds tremendous promise for the treatment of a wide variety of illnesses and conditions, from spinal cord injury to autism. However, much more work is necessary to translate stem cell research into safe and effective therapies...
25 April 2016 - by Dr Julia Hill 
A study has found that stem cells from older people accumulate high numbers of mitochondrial DNA mutations, which could limit their therapeutic value...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.